TABLE 1.
Characteristics of the study cohort.
| Characteristic | Study cohort, n = 3903 |
|---|---|
| Age, years, mean ± SDa | 47 ± 18.2 |
| Sex, n (%) | |
| Male | 1659 (42.5) |
| Female | 2244 (57.5) |
| Race, n (%) | |
| Black or African American | 217 (5.5) |
| Otherb | 475 (12.2) |
| White | 3211 (82.3) |
| Ethnicity, n (%) | |
| Hispanic | 263 (6.7) |
| Unknown | 367 (9.4) |
| Non-Hispanic | 3273 (83.9) |
| Epilepsy diagnosis, n (%) | |
| Positive | 2733 (70.0) |
| Negative | 1170 (30.0) |
| Number of encounters, N | 8415 |
| Diagnosis, N (%) | |
| Epilepsy and recurrent seizures | 5363 (63.7) |
| Convulsions seizures | 1149 (13.7) |
| Syncope | 8 (.1) |
| Top ASMs, N (%)c | |
| Lamotrigine | 3134 (37.2) |
| Levetiracetam | 3072 (36.5) |
| Lorazepam | 2131 (25.3) |
| Lacosamide | 1186 (14.1) |
| Top text features, N (%)d | |
| {{“histori”, “seizur”}; {“hx”, ”seizur”}} | 6301 (74.9) |
| {“no”, “seizur”} | 5827 (69.2) |
| {“with”, “epilepsi”} | 5785 (68.7) |
| {{“lamotrigin’}; {“ltg”}} | 4505 (53.5) |
| {“keppra”} | 4337 (51.5) |
| {“focal”} | 4274 (50.8) |
| {“general”, “seizur”} | 3968 (47.2) |
| {{“levetiracetam”}; {“lev”}} | 3892 (46.3) |
| {“febril”} | 3877 (46.1) |
| {“seizur”, “control”} | 3177 (37.8) |
Note: The number of patients is represented by n and the number of visits by N.
Abbreviation: ASM, antiseizure medication.
a
Age at baseline for the first visit in the study period.
b
“Other” includes unknown, declined, American Indian or Alaska Native, Asian, and Native Hawaiian or other Pacific Islander.
c
A full list of ASMs is presented in Table S4.
d
Bag of words for the top 10 text features present in the cohort encounters notes.